Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Trial Profile

Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GO-NICE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Jun 2018 Results of post-hoc analysis of socio- and health-economic parameters of the non nterventional, multicenter, prospective GO-NICE study presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of post-hoc analysis (n=501), were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 08 Nov 2017 Results (n=244) of a post-hoc sub-analysis assessing Golimumab in biologic-naive patients with established ankylosing spondylitis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top